401 related articles for article (PubMed ID: 19718467)
1. Two cases of congenital dysfibrinogenemia associated with thrombosis - Fibrinogen Praha III and Fibrinogen Plzen.
Kotlín R; Reicheltová Z; Malý M; Suttnar J; Sobotková A; Salaj P; Hirmerová J; Riedel T; Dyr JE
Thromb Haemost; 2009 Sep; 102(3):479-86. PubMed ID: 19718467
[TBL] [Abstract][Full Text] [Related]
2. Two novel mutations in the fibrinogen γ nodule.
Kotlín R; Pastva O; Stikarová J; Hlaváčková A; Suttnar J; Chrastinová L; Riedel T; Salaj P; Dyr JE
Thromb Res; 2014 Oct; 134(4):901-8. PubMed ID: 25074738
[TBL] [Abstract][Full Text] [Related]
3. Fibrinogen Nový Jicín and Praha II: cases of hereditary Aalpha 16 Arg-->Cys and Aalpha 16 Arg-->His dysfibrinogenemia.
Kotlín R; Chytilová M; Suttnar J; Riedel T; Salaj P; Blatný J; Santrůcek J; Klener P; Dyr JE
Thromb Res; 2007; 121(1):75-84. PubMed ID: 17408725
[TBL] [Abstract][Full Text] [Related]
4. A novel natural mutation AαPhe98Ile in the fibrinogen coiled-coil affects fibrinogen function.
Riedelová-Reicheltová Z; Kotlín R; Suttnar J; Geierová V; Riedel T; Májek P; Dyr JE
Thromb Haemost; 2014 Jan; 111(1):79-87. PubMed ID: 24108601
[TBL] [Abstract][Full Text] [Related]
5. The fibrinogen Aalpha R16C mutation results in fibrinolytic resistance.
Flood VH; Al-Mondhiry HA; Farrell DH
Br J Haematol; 2006 Jul; 134(2):220-6. PubMed ID: 16846481
[TBL] [Abstract][Full Text] [Related]
6. Dusart Syndrome in a Scandinavian family characterized by arterial and venous thrombosis at young age.
Ramanathan R; Gram J; Feddersen S; Nybo M; Larsen A; Sidelmann JJ
Scand J Clin Lab Invest; 2013 Oct; 73(7):585-90. PubMed ID: 24000886
[TBL] [Abstract][Full Text] [Related]
7. Fibrinogen Šumperk II: dysfibrinogenemia in an individual with two coding mutations.
Kotlín R; Suttnar J; Cápová I; Hrachovinová I; Urbánková M; Dyr JE
Am J Hematol; 2012 May; 87(5):555-7. PubMed ID: 22407772
[TBL] [Abstract][Full Text] [Related]
8. Fibrinogen Caracas V, an abnormal fibrinogen with an Aalpha 532 Ser-->Cys substitution associated with thrombosis.
Marchi R; Lundberg U; Grimbergen J; Koopman J; Torres A; de Bosch NB; Haverkate F; Arocha Piñango CL
Thromb Haemost; 2000 Aug; 84(2):263-70. PubMed ID: 10959699
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of fibrinogen Bicêtre II: a gamma 308 Asn-->Lys mutation located near the fibrin D:D interaction sites.
Marchi RC; Carvajal Z; Boyer-Neumann C; Anglés-Cano E; Weisel JW
Blood Coagul Fibrinolysis; 2006 Apr; 17(3):193-201. PubMed ID: 16575257
[TBL] [Abstract][Full Text] [Related]
10. A novel fibrinogen variant--Liberec: dysfibrinogenaemia associated with gamma Tyr262Cys substitution.
Kotlín R; Sobotková A; Suttnar J; Salaj P; Walterová L; Riedel T; Reicheltová Z; Dyr JE
Eur J Haematol; 2008 Aug; 81(2):123-9. PubMed ID: 18485115
[TBL] [Abstract][Full Text] [Related]
11. Partial deletion of the αC-domain in the Fibrinogen Perth variant is associated with thrombosis, increased clot strength and delayed fibrinolysis.
Westbury SK; Duval C; Philippou H; Brown R; Lee KR; Murden SL; Phillips E; Reilly-Stitt C; Whalley D; Ariëns RA; Mumford AD
Thromb Haemost; 2013 Dec; 110(6):1135-44. PubMed ID: 24048413
[TBL] [Abstract][Full Text] [Related]
12. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I.
Terasawa F; Kani S; Hongo M; Okumura N
Thromb Res; 2006; 118(5):651-61. PubMed ID: 16412498
[TBL] [Abstract][Full Text] [Related]
13. A novel Asp344Val substitution in the fibrinogen gamma chain (fibrinogen Caen) causes dysfibrinogenemia associated with thrombosis.
Robert-Ebadi H; Le Querrec A; de Moerloose P; Gandon-Laloum S; Borel Derlon A; Neerman-Arbez M
Blood Coagul Fibrinolysis; 2008 Oct; 19(7):697-9. PubMed ID: 18832913
[TBL] [Abstract][Full Text] [Related]
14. The mutation in fibrinogen Bicêtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrin.
Grailhe P; Boyer-Neumann C; Haverkate F; Grimbergen J; Larrieu MJ; Anglés-Cano E
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):679-87. PubMed ID: 8292717
[TBL] [Abstract][Full Text] [Related]
15. Fibrinogen residue γAla341 is necessary for calcium binding and 'A-a' interactions.
Park R; Ping L; Song J; Hong SY; Choi TY; Choi JR; Gorkun OV; Lord ST
Thromb Haemost; 2012 May; 107(5):875-83. PubMed ID: 22437918
[TBL] [Abstract][Full Text] [Related]
16. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II).
Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N
Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304
[TBL] [Abstract][Full Text] [Related]
17. Fibrinogen anomalies and disease. A clinical update.
Galanakis DK
Hematol Oncol Clin North Am; 1992 Oct; 6(5):1171-87. PubMed ID: 1400080
[TBL] [Abstract][Full Text] [Related]
18. Fibrinogen Matsumoto I: a gamma 364 Asp-->His (GAT-->CAT) substitution associated with defective fibrin polymerization.
Okumura N; Furihata K; Terasawa F; Nakagoshi R; Ueno I; Katsuyama T
Thromb Haemost; 1996 Jun; 75(6):887-91. PubMed ID: 8822581
[TBL] [Abstract][Full Text] [Related]
19. Fibrinogen Bastia (gamma 318 Asp-->Tyr) a novel abnormal fibrinogen characterized by defective fibrin polymerization.
Lounes KC; Soria C; Valognes A; Turchini MF; Soria J; Koopman J
Thromb Haemost; 1999 Dec; 82(6):1639-43. PubMed ID: 10613648
[TBL] [Abstract][Full Text] [Related]
20. Dysfibrinogen Kagoshima with the amino acid substitution gammaThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule.
Niwa K; Mimuro J; Miyata M; Sugo T; Ohmori T; Madoiwa S; Tei C; Sakata Y
Thromb Res; 2008; 121(6):773-80. PubMed ID: 17854865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
